Published mark

ROCKET PHARMACEUTICALS, INC.

NASDAQ: RCKT. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:1983b7ba-a9df-445e-933b-d06c7b8194a3
SEC CIK
0001281895
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 19, 2026
Newest evidence
Apr 6, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Giovanni Caforio, M.D.Since Apr 6, 2026
Chair
Not published
Independent
Not published8 directors published
Published claims
272 distinct sources
Evidence records
100 pinned
Source conflicts
0None open

Built from 2 distinct sources and 10 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

DIRECTOR APPOINTED

Elisabeth Björk seat on ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.

EffectiveEffective Apr 6, 2026E2

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Chief Operating OfficerChristopher StevensApr 2026currentSource reportedE3
Chief Executive Officer and DirectorGiovanni Caforio, M.D.Apr 2026currentSource reportedE4
Vice President of Finance, Senior Controller Treasurer, Principal Accounting OfficerJohn Militello, CPAApr 2026currentSource reportedE5
Chief Science Gene Therapy OfficerJonathan Schwartz, M.D.Apr 2026currentSource reportedE6
General Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial OfficerMartin Wilson, J.D.Apr 2026currentSource reportedE7
Chief Commercial Medical Affairs OfficerSarbani Chaudhuri, M.B.A.Apr 2026currentSource reportedE8
Chief Medical OfficerSyed Rizvi, M.D.Apr 2026currentSource reportedE9

Board of directors

Evidence

8 directors published. Independence determinations are not published for every director.

DirectorStatusSinceCommitteesClaim
David P. SouthwellIndependence not published2014None publishedSource reportedE2
Elisabeth BjörkIndependence not published2026AUDIT COMMITTEESource reportedE2
Fady MalikIndependence not published2022None publishedSource reportedE2
Gaurav ShahIndependence not published2018None publishedSource reportedE2
Mikael DolstenIndependence not published2024None publishedSource reportedE2
Peter FongIndependence not published2025compensation committeenominating and corporate governance committeeSource reportedE2
Piratip PratumsuwanIndependence not published2026AUDIT COMMITTEESource reportedE2
Roderick WongIndependence not published2018None publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
AUDIT COMMITTEENot publishedElisabeth Björk, Piratip PratumsuwanNot described in the published record
compensation committeeNot publishedPeter FongNot described in the published record
nominating and corporate governance committeeNot publishedPeter FongNot described in the published record
Committee RecordAUDIT COMMITTEE: Chair not stated; Members Elisabeth Björk; Piratip Pratumsuwan
Source reportedE10
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:committee_record:20
Committee AppointmentElisabeth Björk: member, AUDIT COMMITTEE
Source reportedE10
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:committee_appointment:21
Committee AppointmentPiratip Pratumsuwan: member, AUDIT COMMITTEE
Source reportedE10
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:committee_appointment:22
Committee Recordcompensation committee: Chair not stated; Members Peter Fong
Source reportedE10
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:committee_record:23
Committee AppointmentPeter Fong: member, compensation committee
Source reportedE10
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:committee_appointment:24
Committee Recordnominating and corporate governance committee: Chair not stated; Members Peter Fong
Source reportedE10
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:committee_record:25
Committee AppointmentPeter Fong: member, nominating and corporate governance committee
Source reportedE10
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:committee_appointment:26

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerGiovanni Caforio, M.D., Chief Executive Officer and Director, from Apr 6, 2026
Source reportedE4
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:leadership_role:14
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingRCKT (NASDAQ)
Source reportedE1
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:security_listing:27
Security ListingRCKTW (NASDAQ)
Source reportedE1
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:security_listing:28
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 19, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameROCKET PHARMACEUTICALS, INC.
Source reportedE1
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:1983b7ba-a9df-445e-933b-d06c7b8194a3:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
10 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 19, 2026. Cited by 5 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    DEF 14A ny20067122x2_def14a.htm
    sec proxy. Published Apr 6, 2026. Retrieved Sep 2, 2026. Cited by 8 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    RCKT DEF 14A executive officers
    sec filing. Published Apr 6, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    RCKT DEF 14A executive officers
    sec filing. Published Apr 6, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    RCKT DEF 14A executive officers
    sec filing. Published Apr 6, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    RCKT DEF 14A executive officers
    sec filing. Published Apr 6, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    RCKT DEF 14A executive officers
    sec filing. Published Apr 6, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  8. E8
    RCKT DEF 14A executive officers
    sec filing. Published Apr 6, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  9. E9
    RCKT DEF 14A executive officers
    sec filing. Published Apr 6, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  10. E10
    AUDIT COMMITTEE
    governance_people_committees. sec proxy. Cited by 7 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 19, 2026
  • Elisabeth Björk seat on ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.
  • Piratip Pratumsuwan seat on ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.
  • Christopher Stevens executive of ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.
  • Giovanni Caforio, M.D. executive of ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.
  • John Militello, CPA executive of ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.
  • Jonathan Schwartz, M.D. executive of ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.
  • Martin Wilson, J.D. executive of ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.
  • Sarbani Chaudhuri, M.B.A. executive of ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.
  • Syed Rizvi, M.D. executive of ROCKET PHARMACEUTICALS, INC., effective 2026-04-06.
  • Peter Fong seat on ROCKET PHARMACEUTICALS, INC., effective 2025-01-01.
  • Mikael Dolsten seat on ROCKET PHARMACEUTICALS, INC., effective 2024-01-01.
  • Fady Malik seat on ROCKET PHARMACEUTICALS, INC., effective 2022-01-01.
  • Gaurav Shah seat on ROCKET PHARMACEUTICALS, INC., effective 2018-01-01.
  • Roderick Wong seat on ROCKET PHARMACEUTICALS, INC., effective 2018-01-01.
  • David P. Southwell seat on ROCKET PHARMACEUTICALS, INC., effective 2014-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:1983b7ba-a9df-445e-933b-d06c7b8194a3, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/rocket-pharmaceuticals-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership7
  4. Board8
  5. Committees3
  6. Control and voting0
  7. Authority to act4
  8. Financials2
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people15
  17. Subject and corrections6
  18. Evidence10
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:1983b7ba-a9df-445e-933b-d06c7b8194a3
  • Cite this recordROCKET PHARMACEUTICALS, INC.
  • Copy canonical URLregistry.alpha.ac/companies/rocket-pharmaceuticals-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    ROCKET PHARMACEUTICALS, INC.Company
  • Christopher StevensPerson
  • Giovanni Caforio, M.D.Person
  • John Militello, CPAPerson
  • Jonathan Schwartz, M.D.Person
  • Martin Wilson, J.D.Person
  • Sarbani Chaudhuri, M.B.A.Person
  • Syed Rizvi, M.D.Person
  • David P. SouthwellPerson
  • Elisabeth BjörkPerson
  • Fady MalikPerson
  • Gaurav ShahPerson
  • Mikael DolstenPerson
  • Peter FongPerson
  • Piratip PratumsuwanPerson
  • Roderick WongPerson
  • Sections
    OverviewROCKET PHARMACEUTICALS, INC.
  • MonitoringROCKET PHARMACEUTICALS, INC.
  • LeadershipROCKET PHARMACEUTICALS, INC.
  • BoardROCKET PHARMACEUTICALS, INC.
  • CommitteesROCKET PHARMACEUTICALS, INC.
  • Control and votingROCKET PHARMACEUTICALS, INC.
  • Authority to actROCKET PHARMACEUTICALS, INC.
  • FinancialsROCKET PHARMACEUTICALS, INC.
  • GovernanceROCKET PHARMACEUTICALS, INC.
  • RiskROCKET PHARMACEUTICALS, INC.
  • AI oversightROCKET PHARMACEUTICALS, INC.
  • LegalROCKET PHARMACEUTICALS, INC.
  • CompensationROCKET PHARMACEUTICALS, INC.
  • Other published claimsROCKET PHARMACEUTICALS, INC.
  • Coverage gapsROCKET PHARMACEUTICALS, INC.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.